The use of PARP inhibitors has been most successfully exploited in BRCA1/2-deficient breast and ovarian cancers (Sonnenblick et al., 2015), and recently olaparib has been approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients with DDR gene mutations (de Bono et al., 2020; Hussain et al., 2020). The gene discussed is BRCA1; the disease is ovarian carcinoma.